Olivier Bahuaud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Olivier Bahuaud has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Adrien Lemaignen
Infectious Diseases Unit, Centre Hospitalier Régional Universitaire (CHRU) de Tours, Tours, France
3 shared publications - Cécile Le Brun
Service de Bactériologie-Virologie-Hygiène, Centre Hospitalier Régional Universitaire de Tours, Tours, France
3 shared publications - Louis Bernard
Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, Tours, France
2 shared publications - Thomas Chalopin
CHU de Tours, Hématologie, Tours, France
2 shared publications - Adeline Pastuszka
Service de Bactériologie-Virologie, CHRU de Tours, 37044 Tours, France
1 shared publication - Anne-Sophie Valentin
Centre d’Appui pour la Prévention des Infections Associées aux Soins (CPias) de la région Centre Val de Loire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, 37044 Tours, France
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Elsevier in SSRN Electronic Journal
CD8⁺ T-Cell Subset Dynamics As An Immunological Signature Of Favourable Outcome During Anti-Tuberculosis Treatment
Background: Reliable non-sputum-based indicators of tuberculosis (TB) treatment response are needed to support personalized treatment strategies and the use of shorter regimens. Cytotoxic lymphocytes are essential to TB control, but their value as treatment-response biomarkers is incompletely defined. We hypothesized that longitudinal dynamics of cytotoxic lymphocyte subsets during anti-TB treatment could reveal immune signatures associated with favourable treatment response.Methods: The Opti-4TB prospective cohort included adults diagnosed with and treated for drug-susceptible TB and control latent infection (LTBI) individuals. High-dimensional phenotypic characterization was performed using spectral-flow-cytometry on peripheral CD8+ T cells and Natural Killer (NK) cell throughout treatment. Treatment-responsive cell subsets were identified by unsupervised clustering. Their longitudinal dynamics were compared with those of the RISK6 transcriptomic score, used as a correlate of favourable outcome.Findings: In active TB patients, two CD8⁺ effector memory subsets displayed opposing dynamics during treatment: a long-lived population (LLEM; IL7Rα⁺CD27⁺) increased early, while an activated short-lived population (SLEM; CD38⁺HLA-DR⁺) declined. The LLEM/SLEM ratio increased during treatment and converged toward LTBI levels. This ratio mirrored the inverse kinetics of the RISK6 score and was significantly associated with RISK6 both at inter- and intra-individual levels. An activated NK subset (NKdimCD38⁺) also declined during treatment. These findings were reproduced in a validation cohort.Interpretation: The LLEM/SLEM ratio is a consistent flow-cytometry-based immune signature of favorable TB treatment response, reflecting the remodelling of the CD8⁺T-cell adaptive compartment during infection resolution. This cellular signature may complement conventional and transcriptomic approaches for treatment monitoring and the evaluation of new therapeutic regimens in clinical trials.
- 30 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessCD8⁺ T-Cell Subset Dynamics As An Immunological Signature Of Favourable Outcome During Anti-Tuberculosis Treatment
Background: Reliable non-sputum-based indicators of tuberculosis (TB) treatment response are needed to support personalized treatment strategies and the use of shorter regimens. Cytotoxic lymphocytes are essential to TB control, but their value as treatment-response biomarkers is incompletely defined. We hypothesized that longitudinal dynamics of cytotoxic lymphocyte subsets during anti-TB treatment could reveal immune signatures associated with favourable treatment response.Methods: The Opti-4TB prospective cohort included adults diagnosed with and treated for drug-susceptible TB and control latent infection (LTBI) individuals. High-dimensional phenotypic characterization was performed using spectral-flow-cytometry on peripheral CD8+ T cells and Natural Killer (NK) cell throughout treatment. Treatment-responsive cell subsets were identified by unsupervised clustering. Their longitudinal dynamics were compared with those of the RISK6 transcriptomic score, used as a correlate of favourable outcome.Findings: In active TB patients, two CD8⁺ effector memory subsets displayed opposing dynamics during treatment: a long-lived population (LLEM; IL7Rα⁺CD27⁺) increased early, while an activated short-lived population (SLEM; CD38⁺HLA-DR⁺) declined. The LLEM/SLEM ratio increased during treatment and converged toward LTBI levels. This ratio mirrored the inverse kinetics of the RISK6 score and was significantly associated with RISK6 both at inter- and intra-individual levels. An activated NK subset (NKdimCD38⁺) also declined during treatment. These findings were reproduced in a validation cohort.Interpretation: The LLEM/SLEM ratio is a consistent flow-cytometry-based immune signature of favorable TB treatment response, reflecting the remodelling of the CD8⁺T-cell adaptive compartment during infection resolution. This cellular signature may complement conventional and transcriptomic approaches for treatment monitoring and the evaluation of new therapeutic regimens in clinical trials.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Dynamics of the cytotoxic immune response during anti-tuberculosis therapy : identification of host biomarkers for personalized treatment monitoring
Evaluation de la dynamique de la réponse immune cytotoxique au cours du traitement de la tuberculose : Identification de biomarqueurs de l’hôte pour une approche personnalisée du suivi de la réponse au traitement: Au cours des dernières années, la prise en soin de la tuberculose (TB) a connu des avancées majeures, notamment grâce à l’avènement des tests moléculaires rapides et au développement de nouvelles associations thérapeutiques permettant de réduire les durées de traitement. Cependant, l’évaluation de la réponse au traitement demeure complexe, reposant sur des outils cliniques, radiologiques ou microbiologiques souvent subjectifs, longs à interpréter et peu prédictifs d’une évolution favorable. Or, disposer d’indicateurs fiables de l’efficacité thérapeutique est essentiel à la mise en œuvre de stratégies de traitement personnalisées et à l’évaluation de schémas thérapeutiques raccourcis. Dans cette perspective, la recherche de nouveaux biomarqueurs capables de refléter précocement l’efficacité du traitement apparait aujourd’hui comme une priorité. Ces travaux de thèse s’inscrivent dans cette dynamique et visent à identifier des biomarqueurs immunologiques de l’hôte associés à l’évolution clinique au cours du traitement de la TB. Ils s’appuient sur la cohorte prospective OPTI-4TB, conçue pour associer un suivi longitudinal rigoureux, intégrant des données cliniques, biologiques et microbiologiques, à l’évaluation approfondie de la réponse immunitaire des patients traités pour une TB pulmonaire sensible. Dans un premier temps, l’immunophénotypage étendu des populations lymphocytaires cytotoxiques circulantes en cytométrie spectrale a permis de mettre en évidence deux sous-populations de lymphocytes T-CD8⁺ présentant des dynamiques opposées au cours du traitement : Une population avec un profil d’effecteur mémoire à long-terme dont l’abondance augmentait (LLEM : CD8⁺CD45RA⁻CCR7⁻CD27⁺IL7Rα⁺) et une population d’effecteur mémoire activés à courte durée de vie, dont la proportion diminuait progressivement (SLEM : CD8⁺CD45RA⁻CCR7⁻CD38⁺HLA-DR⁺). En parallèle, une sous-population NK activée (CD56dimCD16⁺CD38⁺) diminuait également au cours du traitement. Ces dynamiques cellulaires accompagnaient la guérison clinique observée chez l’ensemble des patients de la cohorte. Les dynamiques inverses deux populations CD8⁺ ont conduit à la définition d’une signature immunologique intégrative sous la forme d’un ratio LLEM/SLEM. De façon intéressante, la dynamique du ratio LLEM/SLEM au cours du traitement était étroitement associée à celle du score transcriptomique Risk6, marqueur validé de réponse favorable au traitement, soulignant le potentiel du ratio comme biomarqueur immunologique précoce de la bonne réponse au traitement. Une partie de ce travail a également porté sur la simplification de la signature phénotypique de ces populations dans une optique de transposition potentielle vers des applications en routine. Un autre volet de ces travaux a exploré l’intérêt des paramètres pharmacocinétiques dans l’appréciation de la réponse au traitement antituberculeux. Les dosages de la rifampicine et de son métabolite actif (25-déacétylrifampicine) ont montré une auto-induction enzymatique rapide entraînant une sous-exposition fréquente pour une posologie standard (10 mg/kg). Bien que ces paramètres ne permettent pas, à eux seuls, de prédire directement la réponse au traitement, ils constituent un levier complémentaire dans une stratégie de suivi personnalisée en favorisant l’identification précoce des patients sous-exposés et l’ajustement individualisé des posologies. En conclusion, ces travaux soulignent l’intérêt d’une approche intégrée combinant immunomonitoring et pharmacocinétique pour le suivi du traitement antituberculeux. Nous proposons ici un nouvel outil immunologique prometteur pour l’évaluation de la réponse au traitement dont la validation dans des cohortes élargies, notamment dans des contextes à forte endémie, représentera une étape clé vers son intégration potentielle dans la pratique clinique et les essais thérapeutiques.
- 9 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Dynamics of the cytotoxic immune response during anti-tuberculosis therapy : identification of host biomarkers for personalized treatment monitoring
Evaluation de la dynamique de la réponse immune cytotoxique au cours du traitement de la tuberculose : Identification de biomarqueurs de l’hôte pour une approche personnalisée du suivi de la réponse au traitement: Au cours des dernières années, la prise en soin de la tuberculose (TB) a connu des avancées majeures, notamment grâce à l’avènement des tests moléculaires rapides et au développement de nouvelles associations thérapeutiques permettant de réduire les durées de traitement. Cependant, l’évaluation de la réponse au traitement demeure complexe, reposant sur des outils cliniques, radiologiques ou microbiologiques souvent subjectifs, longs à interpréter et peu prédictifs d’une évolution favorable. Or, disposer d’indicateurs fiables de l’efficacité thérapeutique est essentiel à la mise en œuvre de stratégies de traitement personnalisées et à l’évaluation de schémas thérapeutiques raccourcis. Dans cette perspective, la recherche de nouveaux biomarqueurs capables de refléter précocement l’efficacité du traitement apparait aujourd’hui comme une priorité. Ces travaux de thèse s’inscrivent dans cette dynamique et visent à identifier des biomarqueurs immunologiques de l’hôte associés à l’évolution clinique au cours du traitement de la TB. Ils s’appuient sur la cohorte prospective OPTI-4TB, conçue pour associer un suivi longitudinal rigoureux, intégrant des données cliniques, biologiques et microbiologiques, à l’évaluation approfondie de la réponse immunitaire des patients traités pour une TB pulmonaire sensible. Dans un premier temps, l’immunophénotypage étendu des populations lymphocytaires cytotoxiques circulantes en cytométrie spectrale a permis de mettre en évidence deux sous-populations de lymphocytes T-CD8⁺ présentant des dynamiques opposées au cours du traitement : Une population avec un profil d’effecteur mémoire à long-terme dont l’abondance augmentait (LLEM : CD8⁺CD45RA⁻CCR7⁻CD27⁺IL7Rα⁺) et une population d’effecteur mémoire activés à courte durée de vie, dont la proportion diminuait progressivement (SLEM : CD8⁺CD45RA⁻CCR7⁻CD38⁺HLA-DR⁺). En parallèle, une sous-population NK activée (CD56dimCD16⁺CD38⁺) diminuait également au cours du traitement. Ces dynamiques cellulaires accompagnaient la guérison clinique observée chez l’ensemble des patients de la cohorte. Les dynamiques inverses deux populations CD8⁺ ont conduit à la définition d’une signature immunologique intégrative sous la forme d’un ratio LLEM/SLEM. De façon intéressante, la dynamique du ratio LLEM/SLEM au cours du traitement était étroitement associée à celle du score transcriptomique Risk6, marqueur validé de réponse favorable au traitement, soulignant le potentiel du ratio comme biomarqueur immunologique précoce de la bonne réponse au traitement. Une partie de ce travail a également porté sur la simplification de la signature phénotypique de ces populations dans une optique de transposition potentielle vers des applications en routine. Un autre volet de ces travaux a exploré l’intérêt des paramètres pharmacocinétiques dans l’appréciation de la réponse au traitement antituberculeux. Les dosages de la rifampicine et de son métabolite actif (25-déacétylrifampicine) ont montré une auto-induction enzymatique rapide entraînant une sous-exposition fréquente pour une posologie standard (10 mg/kg). Bien que ces paramètres ne permettent pas, à eux seuls, de prédire directement la réponse au traitement, ils constituent un levier complémentaire dans une stratégie de suivi personnalisée en favorisant l’identification précoce des patients sous-exposés et l’ajustement individualisé des posologies. En conclusion, ces travaux soulignent l’intérêt d’une approche intégrée combinant immunomonitoring et pharmacocinétique pour le suivi du traitement antituberculeux. Nous proposons ici un nouvel outil immunologique prometteur pour l’évaluation de la réponse au traitement dont la validation dans des cohortes élargies, notamment dans des contextes à forte endémie, représentera une étape clé vers son intégration potentielle dans la pratique clinique et les essais thérapeutiques.
- Open Access
Rapid resistance detection is reliable for prompt adaptation of isoniazid resistant tuberculosis management
- Open Access
- 8 December 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (12) , 2539
Host Immunity and Francisella tularensis: A Review of Tularemia in Immunocompromised Patients
Tularemia, caused by the bacterium Francisella tularensis, is an infrequent zoonotic infection, well known in immunocompetent (but poorly described in immunocompromised) patients. Although there is no clear literature data about the specific characteristics of this disease in immunocompromised patients, clinical reports seem to describe a different presentation of tularemia in these patients. Moreover, atypical clinical presentations added to the fastidiousness of pathogen identification seem to be responsible for a delayed diagnosis, leading to a” loss of chance” for immunocompromised patients. In this article, we first provide an overview of the host immune responses to Francisella infections and discuss how immunosuppressive therapies or diseases can lead to a higher susceptibility to tularemia. Then, we describe the particular clinical patterns of tularemia in immunocompromised patients from the literature. We also provide hints of an alternative diagnostic strategy regarding these patients. In conclusion, tularemia should be considered in immunocompromised patients presenting pulmonary symptoms or unexplained fever. Molecular techniques on pathological tissues might improve diagnosis with faster results.
- 8 December 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (12) , 2539
Open AccessHost Immunity and Francisella tularensis: A Review of Tularemia in Immunocompromised Patients
Tularemia, caused by the bacterium Francisella tularensis, is an infrequent zoonotic infection, well known in immunocompetent (but poorly described in immunocompromised) patients. Although there is no clear literature data about the specific characteristics of this disease in immunocompromised patients, clinical reports seem to describe a different presentation of tularemia in these patients. Moreover, atypical clinical presentations added to the fastidiousness of pathogen identification seem to be responsible for a delayed diagnosis, leading to a” loss of chance” for immunocompromised patients. In this article, we first provide an overview of the host immune responses to Francisella infections and discuss how immunosuppressive therapies or diseases can lead to a higher susceptibility to tularemia. Then, we describe the particular clinical patterns of tularemia in immunocompromised patients from the literature. We also provide hints of an alternative diagnostic strategy regarding these patients. In conclusion, tularemia should be considered in immunocompromised patients presenting pulmonary symptoms or unexplained fever. Molecular techniques on pathological tissues might improve diagnosis with faster results.
- Open Access
- 18 September 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (9) , 3011
Seven Years Leptospirosis Follow-Up in a Critical Care Unit of a French Metropolitan Hospital; Role of Real Time PCR for a Quick and Acute Diagnosis
(1) Background: Leptospirosis infection can lead to multiple organ failure, requiring hospitalization in an intensive care unit for supportive care, along with initiation of an adapted antibiotic therapy. Achieving a quick diagnosis is decisive in the management of these patients. (2) Methods: We present here a review of leptospirosis cases diagnosed in the intensive care unit of our hospital over seven years. Clinical and biological data were gathered, and we compared the differences in terms of diagnostic method. (3) Results: Molecular biology method by Polymerase Chain Reaction (PCR) allowed quick and reliable diagnosis when performed in the first days after the symptoms began. Moreover, we identified that sampling blood and urine for PCR was more efficient than performing PCR on only one type of biological sample. (4) Conclusions: Our results confirm the efficiency of PCR for the quick diagnosis of leptospirosis and suggest that testing both blood and urine early in the disease might improve diagnosis.
- 18 September 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (9) , 3011
Open AccessSeven Years Leptospirosis Follow-Up in a Critical Care Unit of a French Metropolitan Hospital; Role of Real Time PCR for a Quick and Acute Diagnosis
(1) Background: Leptospirosis infection can lead to multiple organ failure, requiring hospitalization in an intensive care unit for supportive care, along with initiation of an adapted antibiotic therapy. Achieving a quick diagnosis is decisive in the management of these patients. (2) Methods: We present here a review of leptospirosis cases diagnosed in the intensive care unit of our hospital over seven years. Clinical and biological data were gathered, and we compared the differences in terms of diagnostic method. (3) Results: Molecular biology method by Polymerase Chain Reaction (PCR) allowed quick and reliable diagnosis when performed in the first days after the symptoms began. Moreover, we identified that sampling blood and urine for PCR was more efficient than performing PCR on only one type of biological sample. (4) Conclusions: Our results confirm the efficiency of PCR for the quick diagnosis of leptospirosis and suggest that testing both blood and urine early in the disease might improve diagnosis.
- Open Access
- 8 March 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 238
Severe infections due to Francisella tularensis ssp. holarctica in solid organ transplant recipient: report of two cases and review of literature
Tularemia is a rare zoonotic infection caused by bacterium Francisella tularensis. It has been well described in immunocompetent patients but poorly described in immunocompromised patients notably in solid organ transplant recipients. We report here two cases of tularemia in solid organ transplant recipients including first case after heart transplant. We also carried out an exhaustive review of literature describing characteristics of this infection in solid organ transplant recipients.
- 8 March 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 238
Open AccessSevere infections due to Francisella tularensis ssp. holarctica in solid organ transplant recipient: report of two cases and review of literature
Tularemia is a rare zoonotic infection caused by bacterium Francisella tularensis. It has been well described in immunocompetent patients but poorly described in immunocompromised patients notably in solid organ transplant recipients. We report here two cases of tularemia in solid organ transplant recipients including first case after heart transplant. We also carried out an exhaustive review of literature describing characteristics of this infection in solid organ transplant recipients.
- Open Access
- 17 December 2018
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 18 (1) , 665
Acute Tibial osteomyelitis caused by intraosseous access during initial resuscitation: a case report and literature review
Intra-osseous (IO) access is recommended in cases of pre-hospital emergency or resuscitation when intravascular (IV) route is difficult or impossible. Despite recent improvement in IO devices and increasing indications, it remains rarely used in practice. Various complications have been reported but are uncommon. We report a case of massive acute tibial osteomyelitis in an adult male three months after an IO catheter insertion for emergency drug infusion. We review the literature on association between IO access and acute osteomyelitis in children and adults. Emergency-care givers and radiologists should be informed about this infrequent complication in order to make early diagnosis and initiate adequate antibiotic therapy.
- 17 December 2018
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 18 (1) , 665
Open AccessAcute Tibial osteomyelitis caused by intraosseous access during initial resuscitation: a case report and literature review
Intra-osseous (IO) access is recommended in cases of pre-hospital emergency or resuscitation when intravascular (IV) route is difficult or impossible. Despite recent improvement in IO devices and increasing indications, it remains rarely used in practice. Various complications have been reported but are uncommon. We report a case of massive acute tibial osteomyelitis in an adult male three months after an IO catheter insertion for emergency drug infusion. We review the literature on association between IO access and acute osteomyelitis in children and adults. Emergency-care givers and radiologists should be informed about this infrequent complication in order to make early diagnosis and initiate adequate antibiotic therapy.